
Anthem Selects Gilead as Primary Supplier of Hepatitis C Drugs
Health insurer Anthem Inc has reached a deal under which Gilead Sciences Inc's hepatitis C drug Harvoni will be the primary treatment for patients infected with the most common strain of the liver-destroying virus.
Gilead
Sciences
Health insurer Anthem Inc on Thursday said it reached a deal under which Inc's hepatitis C drug Harvoni will be the primary treatment for patients infected with the most common strain of the liver-destroying virus.
Anthem said the deal effectively lowers its hepatitis C treatment costs.
Last month, AbbVie Inc began sales of a competing drug, Viekira Pak, at a similar list price. Express Scripts Holding Co, the largest US pharmacy benefit manager,
However, CVS has also
Read more:
Source: Reuters
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.